Email this article Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
- Authors: Kravchenko AV1
-
Affiliations:
- Центральный НИИ эпидемиологии Роспотребнадзора, Москва
- Issue: Vol 85, No 11 (2013)
- Pages: 125-129
- Section: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/31409
- ID: 31409
Cite item
Full Text
Abstract
The paper gives the results of international trials of and guidelines for the use of maraviroc, the first CCR5 receptor antagonist, in treatment regimens for HIV-infected patients. The trials have convincingly shown that the maraviroc-containing antiretroviral therapy (ART) regimens are highly effective and safe for R5-tropic HIV-infected patients regardless of previous ART, baseline HIV RNA levels, and CD4+ lymphocyte count. Maraviroc can be recommended for HIV-infected patients who have previously received ART and who have been found to have a R5-tropic virus. The changes in the ART regimen and inclusion of maraviroc may be associated with both an ineffective previous treatment regimen and therapy-induced adverse events. In 2012, Russia's first reagent kit for the determination of HIV tropism was put to tests and registered at the Russian Inspectorate for the Protection of Consumer Rights and Human Welfare.
Full Text
##article.viewOnOriginalSite##About the authors
A V Kravchenko
Центральный НИИ эпидемиологии Роспотребнадзора, Москва
Email: kravtchenko@hivrussia.net
References
- Briz V., Poveda E., Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57: 619-627.
- Connor R.I., Sheridan K.E., Ceradini D. et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185: 621-628.
- Scarlatti G., Tresoldi E., Bjorndal A. et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-1265.
- Fatkenheuer G., Pozniak A.L., Johnson M.A. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-1172.
- Лопатухин А.Э., Киреев Д.Е., Куевда Д.А. Разработка единой стандартизованной методики определения тропизма ВИЧ у пациентов перед введением в состав АРВ-терапии препарата - антагониста CCR5-рецепторов. VII Всерос. науч.-практ. конф. с междунар. уч. "Молекулярная диагностика - 2010". Сб. тр. под ред. акад. РАМН В.И. Покровского, т. I. 2010: 59-63.
- Лопатухин А.Э., Киреев Д.Е., Поляков А.Н. и др. Первый опыт применения стандартизированной генотипической методики определения тропизма ВИЧ. Клин лаб диагн 2013; 6: 46-48.
- Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 6.1; November, 2012). European AIDS Clinical Society (http://www.europeanaidsclinicalsociety.org).
- Обследование и антиретровирусная терапия у взрослых и подростков. Клинический протокол для Европейского региона ВОЗ (обновленная версия 2012 г.) ВОЗ, Копенгаген 2012; 91.
- Покровский В.В., Юрин О.Г., Кравченко А.В. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиология и инфекционные болезни. Актуальные вопросы 2012, № 6 (приложение).
- Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS) February 12, 2013 (http://AIDSinfo.nih.gov).
- Gulick R.M., Lalezari J., Goodrich J. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. New Engl J Med 2008; 359 (14): 1429-1441.
- Hardy W.D., Gulick R.M., Mayer H. et al. Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. Acquir Immune Defic Syndr 2010; 55 (5): 558-564.
- Ayoub A., Alston S., Goodrich J. et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS 2010; 24: 2743-2755.
- Gulick R., Fätkenheuer G., Burnside R. et al. 5-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients XIX International AIDS Conference. Washington, DC, USA, July 22-27, 2012; TUPE029.
- Nasta P. Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV) co-infected patients. 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Rome, 2011. abstract WEAB0105.
- Cooper D.A., Heera J., Goodrich J. et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201 (6): 803-813.
- Sax P.E. Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full? J Infect Dis 2010; 201 (6): 797-799.
- Vitiello P., Brudney D., MacCartney M. et al. Responses to Switching to Maraviroc-Based Antiretroviral Therapy in Treated Patients with Suppressed Plasma HIV-1-RNA Load. Intervirology 2012; 55: 172-178.
- Mills A., Mildvan D., Podzamczer D. et al. Safety and immunovirological activity of once daily maraviroc (MVC) in combination with ritonavir-boosted atazanavir (ATV/r) compared to emtricitabine 200mg/tenofovir 300mg QD (TDF/FTC) + ATV/r in treatment-naïve patients infected with CCR5-tropic HIV-1 (Study A4001078): A week 24 planned interim analysis. Program and abstracts of the 17th International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract THLBB203.
- Colbers A., Best B., Wang J. et al. A Comparison of the Pharmacokinetics of Maraviroc during Pregnancy and Postpartum. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013), Atlanta, USA, 2013 Poster №931.
Supplementary files
